XML 41 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue recognition - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Nov. 30, 2019
USD ($)
Oct. 31, 2017
USD ($)
Nov. 30, 2014
USD ($)
Jan. 31, 2014
USD ($)
Aug. 31, 2013
USD ($)
Nov. 30, 2011
USD ($)
compound
Dec. 31, 2019
USD ($)
segment
Number_Distributor
Dec. 31, 2018
USD ($)
deliverable
Dec. 31, 2017
USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Number of operating segments | segment             1    
Number of distributors | Number_Distributor             3    
Percentage of net product sales             10.00%    
Contract with customer, liability             $ 11.7 $ 12.9  
Performance obligations satisfied in current period             3.9 0.0  
United States                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Net product sales             101.0 92.0 $ 28.8
Non-US                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Net product sales             190.3 171.0 145.2
Licensing And Collaboration Agreement                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Performance obligations satisfied in current period $ 15.0 $ 20.0 $ 10.0 $ 7.5 $ 10.0        
Additions           $ 30.0      
Revenue, remaining performance obligation, amount           $ 30.0      
Revenue, remaining performance obligation, expected timing of satisfaction, period           2 years      
Revenue             15.2 $ 0.2 $ 20.3
Collaborative Arrangement | Roche And Sma Foundation                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Collaborative arrangements number of compounds in preclinical development | compound           3      
Collaborative arrangements number of significant deliverables | deliverable               2  
Research And Development Event Milestones | Licensing And Collaboration Agreement                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Revenue recognition, remaining milestone, potential achievements             72.5    
Revenue recognition, milestone, potential achievements             135.0    
Potential net sales milestones | Licensing And Collaboration Agreement                  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                  
Revenue recognition, milestone, potential achievements             $ 325.0